An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)

drug protocol number
178-CL-206A
drug sponsor
Astellas
drug study
Mirabegron
drug trial site
King Abdulaziz University Hospital (Jeddah)
drug status
Rejected
drug phase